Lilly’s tirzepatide more potent than Novo’s semaglutide, but higher discontinuation: Data Byte

Head-to-head and cross-trial comparisons indicate Lilly’s tirzepatide bests Novo’s semaglutide on multiple efficacy metrics for Type II diabetes, but saw a higher rate of patients discontinuing treatment due to adverse events. 

Eli Lilly and Co. (NYSE:LLY) reported data Thursday from the Phase III SURPASS-2 trial, which compared 5 mg, 10 mg and 15 mg doses of tirzepatide, a GIP and GLP-R1 co-agonist, with 1 mg of GLP-R1 agonist Ozempic semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO)...